Navigation Links
Dr. Jay Calvert MD Announces Details on New Patent-Protected Investigational Breast Implants
Date:1/27/2010

LOS ANGELES, Jan. 27 /PRNewswire/ -- Los Angeles-based plastic surgeon, Dr. Jay Calvert, posted more information about the IDEAL breast implants on his blog. He discussed the frequently asked questions about this new product and discussed when it would be available to the public for a clinical trial.

Board-certified Dr. Jay Calvert was chosen as one of the investigators of the new IDEAL breast implants. These implants are known to have the same result as that of silicone gel but are much safer. The clinical trial has begun accepting patients who are willing to undergo the procedure and commit to follow up check ups for the next 10 years.

More and more women are turning to cosmetic surgeries such as breast augmentation and rhinoplasty in order to enhance their looks. The increase in the demand for these types of operations have paved the way for new procedures and tools to be developed in order to ensure the safety of the patients. Among these new developments is the IDEAL breast implant.

"This [IDEAL breast implant] is the first improvement in the basic design of the saline-filled breast implant since it was introduced over 30 years ago,'' explained Dr. Calvert when asked about the new product. The IDEAL breast implant is saline-filled and structurally lowered in order to fit better to the chest wall. It was also designed so that it doesn't wrinkle and would feel and look natural.

The clinical trial for this new product is currently ongoing and patients are being selected to undergo the treatment. The trial program specifies that the patient must pay for the breast augmentation; however, if they are able to complete the 10-year clinical trial, then they will be able to receive some financial benefit. Dr. Calvert, MD, FACS, who is one of the surgeons performing this clinical trial, said that it is like an insurance policy; the company will put part of the patient's payment in her trust fund, and after 10 years, the trust fund is expected to grow to about 10000 U.S. Dollars. Dr. Calvert added that "women who entered the study will then have the comfort of knowing that there's money for them at the end of the study, if they do all their follow-ups and complete the study properly." Even though Dr. Calvert is optimistic about this new breast augmentation technique, he still adds that, "if problems come up and we need to draw upon that money and stop the study, then there's money there to do that."

Certified by the American Board of Plastic Surgery, Dr. Calvert also performs other cosmetic surgeries including breast augmentation, post-bariatric surgery, face-lift and rhinoplasty among others. He is based in Los Angeles, California and sees new patients at his two offices in Beverly Hills and Newport Beach.

Press Release Contact Information:

JayCalvertMD.com

1-888-895-5605

dr.calvert09@gmail.com

This release was issued through WebWire(R). For more information visit http://www.webwire.com.

SOURCE Dr. Jay Calvert MD - Los Angeles Plastic Surgeon

RELATED LINKS
http://www.JayCalvertMD.com

'/>"/>

SOURCE Dr. Jay Calvert MD - Los Angeles Plastic Surgeon
Copyright©2010 PR Newswire.
All rights reserved

Related medicine news :

1. Catholic Health Initiatives Makes $10 Million Investment in Calvert Foundations Community Investment Notes
2. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
3. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
4. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
5. HEI, Inc. Announces Sale of RFID Division Assets
6. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
7. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
8. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
9. Brooke Franchise Corporation Announces Selected July Results
10. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
11. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 10, 2016 , ... Ongoing news of the ravages ... Association™ (ALCA) to conduct a survey that takes a closer look at cases of ... the prevalence and causes of TBI among the aging population, and identifies the challenges ...
(Date:2/10/2016)... ... February 10, 2016 , ... United Benefit Advisors (UBA), the ... addition to its growing list of Partner Firms. S.S. Nesbitt is headquartered ... to Huntsville and in between. , Harnessing the experience and insights of the ...
(Date:2/10/2016)... , ... February 10, 2016 , ... AxoGen, Inc. (NASDAQ: ... report results for the fourth quarter and full year ended December 31, 2015 on ... conference call and webcast for the investment community following the release at 4:30 PM ...
(Date:2/10/2016)... ... ... AHRA: The Association for Medical Imaging Management announced today ... as keynote speaker at the organization’s 2016 Spring Conference. Fox’s topic, Lead with ... with their own organizational staff and leadership. , “I am so excited ...
(Date:2/10/2016)... ... February 10, 2016 , ... For additional information contact ... , Pioneering book "Better with Age: The Ultimate Guide to Brain Training" by award-winning ... improve memory. The book’s publication date is March 16, 2016. A free review ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... , February 10, 2016 --> --> ... Japan .  --> Japan .  --> A ... With submission, Shire continues to strengthen ... With submission, Shire continues to strengthen its presence ... submission, Shire continues to strengthen its presence ...
(Date:2/10/2016)... SEATTLE , Feb. 10, 2016  Resolve ... potentially transformative new approaches to the treatment of ... completion of a multiple ascending dose study in ... lead compound RSLV-132. --> ... double-blind, placebo-controlled multiple ascending dose study of RSLV-132 ...
(Date:2/10/2016)... YORK , Feb. 10, 2016 Immune ... biopharmaceutical company, announced today that it has filed a ... Leukemia and other cancers. --> ... treating cancer by administration of Ceplene (histamine dihydrochloride) in ... provides methods of predicting the efficacy of Ceplene and ...
Breaking Medicine Technology: